Cytomegalovirus (CMV) is the most common virus you’ve never heard of. In the U.S., one in three children will be infected by age five, and more than will have been infected by age 40.
While most people show few to no symptoms of infection, those with weakened immune systems—including babies, pregnant women, and people who have received organ, stem cell, or bone marrow transplants—often face severe, life-threatening disease.
The FDA-approved medication Ganciclovir can combat the most dangerous CMV infections. However, it can be toxic, potentially accumulating to poisonous levels in the body. As a result, transplant patients can only be on Ganciclovir for limited intervals and the drug is not recommended for use by infants or pregnant women.
Pregnant women with a CMV infection face an additional likelihood of miscarriage or risk passing the infection on to their fetus, which is the .
Researchers from the University of Notre Dame, and , have teamed up to develop a technology to reduce the toxicity of Ganciclovir and ultimately reduce the dangers of the drug for patients most vulnerable to CMV. Their project is supported by the National Institutes of Health, and aligns with the University’s to advance human health and wellness through interdisciplinary biomedical research.
“Once you have CMV, you have it for life. You can even reactivate the latent virus in your body if you experience immunity suppression, like in pregnancy or as a transplant patient,” said Perez Romero, an associate professor in the at Notre Dame who has spent her career studying this overlooked virus. “We want to find an alternative treatment option.”
Initially, Perez Romero and her lab were exploring antibodies as an alternative to Ganciclovir. Antibodies play an important role in the immune system, acting as a beacon for macrophage cells, which destroy viruses and infected cells in the body. For some viruses, antibodies can also physically block viruses from causing an infection.
To obtain antibodies that specifically target the virus, Perez Romero worked with the to access blood samples from transplant patients, since this population is particularly vulnerable to multiple CMV infections after transplantation. Addison Hill and Kathryn Currie, graduate students in Perez Romero’s lab, isolated antibodies from the patient samples and saw that when these antibodies reached CMV-infected cells, they were absorbed by the virus—a defense mechanism to hide the antibodies, and thus the virus, from macrophage cells.
Hoping to exploit this viral defense mechanism, Perez Romero reached out to Nallathamby, a nanoparticle engineer with expertise in developing targeted therapeutics.
One of Nallathamby’s patent-pending technologies addresses chronic wound infections using resorbable polymer nanoparticles made of FDA-approved materials. Perez Romero asked him if these particles, which were initially made to steadily deliver and release antibiotics over three to five days, could do the same with Ganciclovir by encapsulating and transporting the drug to only CMV-infected cells.
Although he believed encapsulating the drug was possible, Nallathamby predicted the challenge would be allowing the nanoparticles enough time to reach infected cells before controlling how quickly they release the medication.
“Imagine the nanoparticles as a cotton candy ball with colored sugar inside it, but the sugar is the Ganciclovir. "Now you attach a key — the isolated antibody — that fits one specific lock on a CMV-infected cell. You toss the whole thing into a pool of water, representing the body, and need it to reach the lock before the cotton candy dissolves,” said Nallathamby, associate director of the at Notre Dame. “That is the challenge. But we do have ways to control the dissolution rate.”
The goal is to take advantage of CMV’s defense mechanism: as an infected cell draws in the antibody, it would also engulf the attached nanoparticle. Once inside, the nanoparticle would release Ganciclovir as it breaks down.
If successful, this approach could concentrate drug delivery inside infected cells while reducing exposure elsewhere in the body, lowering the risk of toxicity.
Perez Romero and Nallathamby are currently developing a laboratory proof of concept of the technology for treating CMV. Eventually, their goal is to create a treatment option that can help those most vulnerable to CMV infections—pregnant women, infants, and transplant patients— safely access this life-saving drug.
Contact: Brandi Wampler, associate director of story development, 574-631-2632, brandiwampler@nd.edu